Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 94
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
9/1/1988
1.
Phase II/III Randomized Study of Intra-arterial FUDR vs FUDR/BCG-Tumor Vaccine vs FUDR/BCG-Tumor Vaccine/Cyclophosphamide in Patients with Unresectable Liver Metastases from Colorectal Carcinoma (Summary Last Modified 09/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
MGH-CR2
NCI-V88-419B
Last Modified:
11/1/1994
2.
Phase III Study of Neoadjuvant FAMTX (5-FU/DOX/MTX) with Postoperative Randomization to Intraperitoneal FUDR/CF vs Observation for Patients with High-Risk Gastric Cancer (Summary Last Modified 11/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
any age
NCI
MSKCC-94032
NCI-H94-0474
Last Modified:
12/12/2007
 
First Published:
2/1/1996
3.
Phase III Randomized Study of Hepatic Artery Infusion of Floxuridine, Leucovorin Calcium (CF), and Dexamethasone Versus IV Fluorouracil and IV CF in Patients With Hepatic Metastases Secondary to Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
CALGB-9481
ECOG-C9481, NCT00002716
Last Modified:
3/29/2004
 
First Published:
4/1/2001
4.
Phase III Randomized Study of Regional and Systemic Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Patients With Unresectable Colorectal Cancer Metastatic to the Liver
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
NCI-01-C-0093
NCT00020501
5.
Phase III Intravenous Chemotherapy with DAVA/5-FU/MITO-C vs HAI Chemotherapy with DAVA/FUDR/MITO-C for Dukes D Colorectal Carcinoma with Liver Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
MDA-DT-8029
Last Modified:
6/1/1997
6.
Phase III Comparison of Intra-Arterial 5-FUDR vs Intravenous 5-FU in the Treatment of Selected Patients with Hepatic Metastases from Colorectal Carcinoma (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
MAYO-824651
CAN-NCIC-NCCTG824651, NCCTG-824651, SWOG-8491, NCCTG824651
7.
Phase III Intra-Arterial Hepatic Infusion of FUDR vs Intravenous 5-FU for Hepatic Metastases from Colorectal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
POA-59282
8.
Phase III Randomized Study of Regional Chemotherapy with 5-FUDR with or without Hyperthermia for Colorectal Cancer Metastatic to the Liver
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
20 to 75
UCLA-8304203
NCI-V83-0306
Last Modified:
6/1/1997
9.
Phase III Pilot Adjuvant Combination Chemotherapy with ADR/5-FUDR Following Complete Resection of Hepatocellular Carcinoma (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
any age
NCI
NCI-84-C-243
NCI-T85-0012N, T85-0012
10.
Phase III Trial of Hepatic Arterial Infusion of FUdR/CACP vs Hepatic Arterial Infusion of FUdR Alone for Colorectal Cancer Metastatic to the Liver
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
MDA-DM-8491
NCI-V85-0136
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute